Effects of including a palmitic acid-enriched supplement in low and high starch diets on milk production and energy partitioning of primiparous and multiparous dairy cows between mid and late-lactation.

The aim of our study was to assess the effects of low or high-starch diets with or without palmitic acid (C16:0) supplementation on the yield of milk, milk components, and energy partitioning of primiparous and multiparous dairy cows between mid and late-lactation. Thirty-two Holstein cows, 12 primiparous ([mean ± SD] 163 ± 33 d in milk) and 20 multiparous ([mean ± SD] 179 ± 37 d in milk), were used in a split-plot Latin square design. Parity was considered the main plot, and within each plot, treatments were then randomly assigned in a replicated 4 × 4 Latin square with 21 d periods and balanced for carryover effects.

Parasite infections: how inflammation alters brain function.

Parasitic infections can profoundly impact brain function through inflammation within the central nervous system (CNS). Once viewed as an immune-privileged site, the CNS is now recognized as vulnerable to immune disruptions from both local and systemic infections. Recent studies reveal that certain parasites, such as Toxoplasma gondii and Plasmodium falciparum, can invade the CNS or influence it indirectly by triggering neuroinflammation.

Characterization of patients treated at a rare disease referral service: a descriptive study, 2016-2021.

Objective: To analyze the first referral service for rare diseases accredited by the Brazilian Ministry of Health, focusing on referral from the primary healthcare network through to diagnosis.

Methods: This is a descriptive study with patients treated between 2016 and 2021 at a referral hospital service located in Curitiba, Paraná, Brazil. Clinical and epidemiological data were obtained from medical records, as were the results of genetic tests at the hospital's clinical analysis laboratory.

Research and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.

Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-derived products for medicinal and recreational use has expanded their global market availability to meet local community demands. This scenario presents a complex challenge for clinicians, researchers, and industry, as the global appeal of therapeutic uses of CBD is growing more rapidly than the scientific evidence supporting its safety and effectiveness.